Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/IIa Dose Escalation Study in Asia of Repeated Administration of "CYT107" (glyco-r-hIL-7) Add On Treatment in Genotype 1 HCV Infected Patients Resistant To Pegylated Interferon-Alpha and Ribavirin.

Next Previous
Search
Trial Profile

A Phase I/IIa Dose Escalation Study in Asia of Repeated Administration of "CYT107" (glyco-r-hIL-7) Add On Treatment in Genotype 1 HCV Infected Patients Resistant To Pegylated Interferon-Alpha and Ribavirin.

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 09 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Interleukin-7 (Primary) ; Peginterferon alfa; Ribavirin
  • Indications Hepatitis C
  • Focus Adverse reactions
  • Acronyms ECLIPSE-3
  • Sponsors Revimmune SAS

    • Most Recent Events

    • 17 Oct 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 17 Oct 2012 Planned End Date changed from 1 Jun 2011 to 1 Dec 2012 as reported by ClinicalTrials.gov.
    • 06 Dec 2009 Additional lead trial centres and investigators identified as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top